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Introduction
Hypertension affects more than 1.1 billion people (1) and is a major 
risk factor for heart attack, stroke, and congestive heart failure, con-
tributing to more than nine million deaths worldwide each year (2). 
In patients referred to hypertension clinics, adrenal gland tumors 
that constitutively secrete the steroid hormone aldosterone are 
found in about 5% (3); they affect one to ten million people world-
wide. These tumors are virtually always benign, and their surgical 
removal is commonly curative, motivating efforts to make a timely 
and accurate diagnosis. Aldosterone-producing adenoma (APA) 
diagnosis is typically based upon the findings of hypertension, 
elevated plasma aldosterone levels with suppressed plasma renin 
activity (indicating autonomous adrenal aldosterone production), 
imaging evidence of an adrenal tumor, and invasive bilateral adre-
nal vein sampling (AVS) showing increased aldosterone levels in the 
adrenal vein ipsilateral to the tumor (4). Tumor removal is typically 
performed laparoscopically or retroperitoneoscopically (5).
Unfortunately, the screening procedure for APAs is expensive 
and time-consuming. In addition, AVS is an invasive and technically 
challenging procedure that is only available in a limited number of 
tertiary care centers. As a result, many patients are not diagnosed 
and do not receive optimal treatment. (11)C-metomidate PET-CT 
has been proposed as a noninvasive alternative (6). However, lower 
sensitivity and specificity, lack of availability in a typical outpatient 
setting, and high cost are potential concerns, and this procedure is 
not generally recommended by current guidelines (4). With rising 
levels of hypertension in low- and middle-income countries in par-
ticular (1), there is a need for simple and inexpensive new screening 
approaches for potentially curable forms of secondary hyperten-
sion. New pharmacologic strategies for the diagnosis and/or treat-
ment of APAs have the potential to improve patient outcome.
By exome sequencing of APAs and matched normal tissue, 
either of 2 somatic missense mutations in the potassium channel 
KCNJ5 were shown to commonly cause APAs (7). Large multi-
center studies have confirmed these findings and have shown that 
these mutations (G151R and L168R) account for 34%–47% of APAs 
in people of European ancestry (8–10) and 60%–77% of people of 
Asian ancestry (11–14), with differences likely attributable to differ-
ences in disease definition. There is also a striking sex dimorphism 
in European and some Asian cohorts (8, 10, 11, 15, 16); European 
cohorts consistently show that these mutations account for 50%–
60% of women with APAs, but only 20% of men, and KCNJ5 muta-
tions are more prevalent in younger patients (8, 10). A small num-
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genes are integrated into a common site in the genome under 
control of a tetracycline-inducible CMV promoter. Cell lines with 
inducible expression of KCNJ5WT, KCNJ5G151R, or KCNJ5L168R were 
produced (see Methods). While induction of KCNJ5WT expres-
sion had no effect on cell viability, cells expressing KCNJ5G151R or 
KCNJ5L168 died rapidly, an effect we previously demonstrated to 
be Na+ dependent (18).
We measured cellular ATP levels as a proxy for cell viability, 
using a commercially available luciferase assay (23) (see Methods). 
Induction of KCNJ5WT had no effect on ATP levels. In contrast, 
induction of KCNJ5G151R or KCNJ5L168R led to drastically reduced 
ATP levels 72 hours after induction (Figure 1A). This allowed high-
throughput screening for inhibitors that prevented reduction in 
ATP levels upon induction of KCNJ5G151R or KCNJ5L168R.
Conditions were optimized to maximize reproducibility and 
the signal-to-background ratios (S/B) (24) comparing ATP levels 
in uninduced and induced cells. Screening was performed in 384-
well plates; compounds were added 24 hours after plating, and 
channel expression was induced immediately after compound 
addition. ATP levels were measured 72 hours after induction.
Because expression of KCNJ5WT in HEK293 cells does not 
cause lethality (Figure 1A), a different assay for inhibition of this 
channel was required. Overexpression of KCNJ5WT in HEK293 
cells leads to K+ efflux and membrane hyperpolarization (7), an 
effect that is reversible upon inhibition of the channel with the 
potassium channel blocker barium. Changes in membrane poten-
tial were detected using a well-established fluorescence-based 
measure of membrane potential, and the efficacy of the assay was 
demonstrated with inhibition by barium (Figure 1B, see Methods). 
This assay may also detect depolarization by compounds that 
inhibit endogenous K+ channels, which would not be desired due 
to the resulting toxicity.
High-throughput screen for KCNJ5MUT inhibitors. KCNJ5G151R, 
the most frequent mutation in APAs (8), was used for the prima-
ry screen. Levels of ATP in uninduced and induced cells without 
added test compound defined 100% and 0% effect, respectively, 
and served as a proxy for lethality. We screened 73,001 compounds 
from 19 libraries for rescue of KCNJ5G151R-induced lethality, mea-
sured as increased levels of ATP, at a concentration of 10 μM (see 
ber of additional KCNJ5 mutations are very rare causes of APAs (8, 
10, 11). KCNJ5G151R and KCNJ5L168R both modify the channel’s selec-
tivity filter, which normally confers high selectivity of the channel 
for K+ conductance; the mutant channel loses selectivity and shows 
similar conduction of K+ and Na+ (7). This results in Na+ influx, 
leading to membrane depolarization, activation of voltage-gated 
Ca2+ channels, and Ca2+ influx (7). Increased intracellular Ca2+ is 
the signal for both cellular proliferation and aldosterone produc-
tion in adrenal glomerulosa cells (17), thereby accounting for the 
cardinal features of APAs. Evidence that these single mutations are 
sufficient for the formation of a hormone-producing tumor comes 
from the finding of identical or related germline KCNJ5 mutations 
in a rare Mendelian form of early onset and severe hypertension 
due to primary aldosteronism with massive adrenal hyperplasia (7, 
18) as well as a striking case of germline mosaicism with hyperplas-
tic lesions restricted to areas carrying a KCNJ5 mutation (19). Fur-
ther, APAs harboring KCNJ5 mutations have very few additional 
protein-altering somatic mutations (only about 3 per tumor), which 
virtually never alter other genes involved in cell proliferation or 
aldosterone biosynthetic pathways (20).
Inhibition of KCNJ5WT has the potential to cause cardiac side 
effects due to KCNJ5 expression in the atrium, where it contrib-
utes to slowing of the heart rate in response to acetylcholine (21). 
However, loss of K+ selectivity in KCNJ5G151R and KCNJ5L168R chan-
nels as well as loss of sensitivity to the K+ channel blockers barium 
(7) and tertiapin-Q (22) suggest that the pore of mutant channels is 
sufficiently altered to enable small molecules to block ion passage 
through the mutant, but not the WT, channel.
These observations motivated efforts to identify specific 
inhibitors of both KCNJ5G151R and KCNJ5L168R (both mutations are 
hereafter referred to as KCNJ5MUT) channels that do not inhibit 
KCNJ5WT and might be used as diagnostic or therapeutic agents 
for APAs harboring these mutations.
Results
Development of screening assays for inhibitors of KCNJ5MUT and 
KCNJ5WT. To screen for inhibitors of mutant and WT KCNJ5 chan-
nels, we generated stable HEK293 cell lines using the commercial-
ly available Flp-In T-REx System, in which single copies of desired 
Figure 1. Establishment of screening assays for KCNJ5MUT and KCNJ5WT inhibition. (A) Reduced ATP levels following induction of KCNJ5G151R or KCNJ5L168R, 
but not KCNJ5WT, in HEK293 cells. Cell survival was measured using an ATP-based viability assay with luminescence as a read-out in stable inducible cell 
lines in the uninduced and induced states. Whereas induction of KCNJ5WT expression had no significant effect on ATP levels, induction of KCNJ5G151R and 
KCNJ5L168R led to a significant decrease in ATP levels. P values represent 2-tailed unpaired Student’s t test comparing uninduced vs. induced for each line.  
n = 8 for each condition, 2,000 cells per well (WT and G151R) or 4,000 cells per well (L168R). Bars represent mean, and error bars represent SD. (B) Evalua-
tion of the KCNJ5WT membrane potential assay using BaCl2 using a standard curve of BaCl2 concentrations. Depolarization caused by increasing BaCl2 con-
centrations leads to an increase in fluorescence. Relative fluorescence at 2 mM BaCl2 was defined as 100%. Data were fitted with a 4-parameter nonlinear 
regression of log-dose versus response. n = 6. Dots represent mean, error bars represent SD.
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Figure 2. Structure activity rela-
tionship of macrolide inhibition 
of KCNJ5G151R. Select compounds 
are shown. The locations of deso-
samine and cladinose moieties 
are indicated on the roxithro-
mycin structure. Values of IC50 
against KCNJ5G151R are given for 
active compounds. See Table 1 for 
detailed screen results.
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Table 2). Some other potent inhibitors of KCNJ5G151R channels, e.g., 
NSC18883 and KC-159, demonstrated either high IC50 values or 
low maximum inhibition of KCNJ5L168R channels.
Screen for KCNJ5WT inhibition. To determine the effect of these 
compounds on KCNJ5WT channels, the compounds were also tested 
for inhibition of KCNJ5WT by measurement of membrane potential 
after induction in the presence and absence of drug. Eight macro-
lides or macrolide derivatives tested had no significant effect on 
KCNJ5WT channels; several of these, including roxithromycin and 
clarithromycin, showed robust inhibition of both KCNJ5G151R and 
KCNJ5L168R (Supplemental Table 2 and Figure 2). Nonmacrolide 
compounds typically were not selective for mutant channels or did 
not robustly inhibit both KCNJ5G151R and KCNJ5L168R (Supplemen-
tal Table 2 and Supplemental Figure 1).
Macrolides are potent inhibitors of KCNJ5MUT, but not KCNJ5WT. 
Macrolides feature a many-membered lactone ring with one or 
more deoxy sugars attached (25). Those with antibiotic activity 
inhibit protein synthesis by binding of the desosamine sugar and 
the lactone ring to bacterial 23S ribosomal RNA (26). Binding to 
other targets produces antiinflammatory activity (27) and stimula-
tion of gastrointestinal motility (28), which can have clinical utility.
To further characterize the structure-activity relationship and 
inhibitory characteristics of the macrolide series, we screened 
14 macrolides and their derivatives in 10-point dilution curves 
(Table 1 and Figure 3). This analysis confirmed potent effects of 
some macrolide antibiotics, including roxithromycin and clar-
ithromycin, but demonstrated negligible activity of others, such as 
flurithromycin. The inhibitory activity of roxithromycin and clar-
ithromycin was greater than that of erythromycin. Clarithromycin 
differs from erythromycin only by methylation of the hydroxyl 
group at the 6 position of the lactone ring; roxithromycin differs 
only by an N-oxime side chain on the lactone ring (Figure 2). 
Methods). Of all compounds, 94.6% showed less than a 10% effect, 
and 398 compounds (0.5%) showed at least a 33.3% effect. Upon 
repeat testing, 92 distinct compounds (0.1% of all compounds from 
the initial screen) produced a 33.3% or greater increase in ATP 
(Supplemental Table 1; supplemental material available online 
with this article; https://doi.org/10.1172/JCI91733DS1).
Among these 92 hits, 31 produced a more than 66.6% mean 
increase in ATP. These included 6 series of structurally related 
compounds. One of these comprised 2 macrolide antibiotics — 
roxithromycin and erythromycin (see Figure 2 for structures). 
The others were a structural series of compounds from the 
ChemDiv library (http://www.chemdiv.com/) (4 compounds 
from D089, 3 compounds from 3132, 2 each from G281, F471, 
and E612; Supplemental Figure 1). Notably, compounds from 
ChemDivD089 and ChemDivE612 share an aniline or benzyl-
amine derivative connected to a benzofuran (in D089) or isoin-
doline (in E612) derivative, respectively.
We next screened these 92 compounds in dose-response 
assays along with 6 additional compounds sharing structural 
similarity to active macrolide antibiotics. Each compound was 
tested at concentrations of 0.12 μM, 0.37 μM, 1.1 μM, 3.3 μM, and 
10 μM. Of these 98 compounds, 91 showed a dose response on 
KCNJ5G151R. The results revealed roxithromycin as the most potent 
KCNJ5G151R inhibitor in this assay (IC50 0.37 μM; Supplemental 
Table 2). Remarkably, virtually complete rescue of ATP level was 
achieved, and microscopy revealed vital cells.
All 98 compounds were also tested for inhibition of the other 
common mutation in APAs, KCNJ5L168R. Thirty-six compounds 
showed a dose response for this channel as well; these included 
the macrolide compounds roxithromycin, roxithromycin-D7, 
N-demethyl roxithromycin, erythromycin A oxime, clarithro-
mycin, erythromycin estolate, and erythromycin (Supplemental 













Roxithromycin 0.22 9.92 105.92 0.69 3.96 81.39 No fit
Roxithromycin-D7 0.58 1.67 96.22 0.68 3.95 70.07 No fit
Idremcinal (EM574) 0.60 6.38 93.39 1.99 -1.28 66.69 No fit
Pseudo erythromycin A enol ether 0.65 1.58 11.13 No Fit NA NA No fit
Clarithromycin 0.71 6.40 83.09 1.72 2.35 55.70 No fit
n-Demethyl roxithromycin 0.82 4.50 96.20 1.18 1.12 76.95 No fit
Erythromycin B 1.23 7.15 84.36 4.73 1.62 80.00 No fit
Erythromycin A oxime  
 (roxithromycin impurity C)
2.88 2.49 84.11 8.13 0.65 60.00 No fit
Azithromycin 5.69 5.11 32.00 8.05 0.71 12.01 No fit
Anhydro-erythromycin A 8.60 5.61 60.00 No fit NA NA No fit
Erythromycin C 9.19 6.72 75.00 12.18 1.41 18.43 No fit
Erythromycin 10.53 3.55 90.00 11.76 0.71 25.00 No fit
Dirithromycin 15.80 1.31 18.29 No fit NA NA No fit
Flurithromycin No fit NA NA No fit NA NA No fit
Results of a 4-parameter nonlinear regression of log-dose versus response of macrolides and their derivatives (KCNJ5G151R, KCNJ5L168R, and KCNJ5WT). 
Compounds were tested at 20, 10, 5, 2.5, 1.25, 0.625, 0.3125, 0.1563, 0.0781, and 0.0391 μM concentrations in technical triplicate. IC50, minimum, and 
maximum inhibition are estimated from the fitted curves. Examples of dose-response curves are shown in Figure 2.
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nels with no inhibition of KCNJ5WT (Figure 4 and Supplemental 
Table 3). These findings suggest the ability to develop drugs that 
retain selective inhibition of mutant KCNJ5 channels without anti-
biotic or gastrointestinal motility activities.
Electrophysiology demonstrates direct inhibition of KCNJ5MUT 
by roxithromycin and synthesized compounds. While KCNJ5 chan-
nels exist as heterotetramers with KCNJ3 and as homotetramers 
in heart (34), their subunit composition in the adrenal gland is cur-
rently unknown. To directly demonstrate that macrolides are inhib-
iting mutant KCNJ5 channels, we performed electrophysiology of 
HEK293T cells expressing KCNJ5 homotetramers or KCNJ5/KCNJ3 
heterotetramers (7). Currents were measured by the whole-cell 
patch-clamp technique (7, 18). Figure 5A shows cation currents of 
heterotetramers recorded in physiological solutions (high extracel-
lular Na+, high intracellular K+) (7). Expression of KCNJ3/KCNJ5WT 
channels resulted in inwardly rectifying K+ currents and a negative 
reversal potential as a result of high K+ conductance. Consistent with 
published results (7), expression of KCNJ3/KCNJ5G151R channels 
caused marked depolarization as a result of Na+ conductance. Addi-
tion of 20 μM roxithromycin led to almost complete inhibition of 
KCNJ3/KCNJ5G151R currents across all voltages tested. Of note, a shift 
of the reversal potential to more negative voltages was observed after 
addition of roxithromycin, consistent with inhibition of the depolar-
izing Na+ conductance. Similar results were obtained for KCNJ3/
KCNJ5L168R. The remaining current for KCNJ3/KCNJ5L168R may be a 
potassium current because it was blocked by the known potassium 
channel pore-blocker barium. In contrast, roxithromycin showed 
no inhibition of potassium currents in KCNJ3/KCNJ5WT channels, 
and currents showed normal sensitivity to barium in the presence 
of roxithromycin. Parallel studies of KCNJ5G151R and KCNJ5L168R 
homotetramers confirmed these results, and no effect on KCNJ5WT 
homotetramers was seen. KCNJ5G151R homotetramers demonstrated 
80% inhibition with 20 μM roxithromycin and 53% inhibition with 
10 μM roxithromycin (Supplemental Figure 2), suggesting that IC50s 
for current inhibition are higher than those for rescue of cellular 
lethality. These results demonstrate direct inhibition by roxithromy-
cin of channels containing KCNJ5 mutations. Similarly, PLUX37 and 
PLUX38, which were tested as representative synthesized inhibitors 
without antibiotic or motilide activity, demonstrated inhibition of 
KCNJ5MUT without effect on KCNJ5WT in electrophysiological studies 
at a 10 μM concentration (Figure 6).
These groups may stabilize the interaction between the macro-
lides and the mutant channel. Other modifications of the lactone 
ring in azithromycin and flurithromycin diminish or eliminate 
inhibition of KCNJ5MUT, supporting interaction of ring constitu-
ents with mutant channels. In addition, the cladinose sugar of 
roxithromycin appears to be critical, since its removal in decladi-
nose roxithromycin and telithromycin results in loss of inhibition 
of KCNJ5MUT (Figure 2). Erythromycin B showed greater activity 
than erythromycin C and A, other components of erythromycin, 
suggesting that hydroxylation at the 12 position, which is present 
in most macrolides, may decrease anti-KCNJ5MUT activity.
In addition to macrolide antibiotics, nonantibiotic macro-
lide derivatives, such as the motilin receptor agonist idremcinal 
(EM 574) (28, 29), were also potent and selective inhibitors of 
KCNJ5MUT (idremcinal IC50 0.60 μM for KCNJ5
G151R and 1.99 μM 
for KCNJ5L168R, no dose response for KCNJ5WT; Figure 2 and Table 
1). Several other compounds with macrolide structures, including 
troleandomycin, josamycin, kitasamycin, oleandomycin, oligo-
mycin C, rapamycin, spiramycin, dirithromycin, rondomycin, and 
natamycin, had little or no activity against KCNJ5G151R in the pri-
mary screen (see Figure 2 for selected structures).
Synthesis of macrolide derivatives without antibiotic or moti-
lide activity. The use of macrolide antibiotics is associated with a 
comparatively low risk of Clostridium difficile infection (30), and 
maintenance treatment with macrolides has been suggested for 
patients with frequent exacerbations of chronic obstructive pul-
monary disease (31), cystic fibrosis (32), and non–cystic fibrosis 
bronchiectasis (33). Yet for the treatment of patients with pri-
mary aldosteronism, the potential induction of pathogen resis-
tance through antibiotic treatment or increased gastrointestinal 
side effects through motilide activity would not be desired. We 
thus sought to identify compounds that retain selective channel 
inhibition without antibiotic or motilide activity, as these would 
have the most potential for clinical use as KCNJ5MUT inhibitors. In 
the development of idremcinal, compounds were identified that 
lacked both antibiotic and motilide activity (28). We synthesized 
several of these compounds (see Methods), confirmed their lack 
of antibiotic activity using the Kirby-Bauer disk diffusion assay 
(Supplemental Table 3, see Methods), and tested intermediates 
and target compounds for their effects on KCNJ5MUT. PLUX38, -36, 
-37, and -33 all showed significant inhibition of both mutant chan-
Figure 3. Dose-response curves of lead macrolide compounds on WT and mutant KCNJ5. Dose-response curves of roxithromycin, clarithromycin, and 
idremcinal on activity of WT and mutant (G151R and L168R) KCNJ5 are shown. For mutant KCNJ5, percentage of inhibition denotes increase in ATP, 
measured by luminescence, in the presence of drug. For WT KCNJ5, percentage of inhibition denotes change in membrane potential in the presence of 
drug (see Methods). Compounds were tested in technical triplicates at 20, 10, 5, 2.5, 1.25, 0.625, 0.3125, 0.1563, 0.0781, and 0.0391 μM concentrations. 
Data were fit with a 4-parameter nonlinear regression of log-dose versus response. While inhibition of mutant channels showed a strong dose-response 
relationship with all 3 compounds, there was no significant inhibition of WT channels. See Table 1 for inhibition data.
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Roxithromycin inhibits 
KCNJ5MUT-induced aldosterone 
production in human adrenal-
derived H295R cells. To assess 
effects of KCNJ5 inhibition 
on aldosterone production, 
we used the HAC15 cell line 
(a subclone of NCI-H295R, 
derived from human adreno-
cortical carcinoma and a com-
monly used in vitro model of 
zona glomerulosa aldosterone 
production; refs. 35, 36). We 
stably transduced cells with 
KCNJ5WT, KCNJ5G151R, and 
KCNJ5L168R or empty vector 
control and measured aldoste-
rone production from superna-
tants. Aldosterone production 
was about 5-fold increased 
in cells expressing KCNJ5MUT 
channels. Importantly, rox-
ithromycin inhibited aldoste-
rone production in a dose-
dependent fashion in cells 
expressing either KCNJ5G151R 
or KCNJ5L168R (Figure 5B), 
whereas levels showed virtual-
ly no change in cells expressing 
KCNJ5WT. Aldosterone levels in 
cells expressing KCNJ5MUT did 
not decrease to the levels of 
control cells, possibly because 
aldosterone accumulates in the 
supernatant and inhibition is 
not instantaneous. Membrane 
depolarization resulting from 
Na+ conductance of KCNJ5MUT 
is known to induce expression 
of CYP11B2, encoding aldoste-
rone synthase. This enzyme 
catalyzes the 3 terminal steps 
in aldosterone biosynthesis 
(hydroxylation at positions 
C11 and C18 of the steroid 
nucleus, followed by oxida-
tion at position C18). Accord-
ingly, we measured expression 
of CYP11B2 by quantitative 
PCR (qPCR) in NCI-H295R 
cells transiently transfected 
with KCNJ5WT, KCNJ5G151R, and 
KCNJ5L168R. Consistent with 
published results (37), cells 
transfected with KCNJ5G151R 
or KCNJ5L168R showed an 
approximately 7-fold increase 
Figure 4. Structures of synthesized compounds with and without inhibition of mutant KCNJ5. Values of IC50 for 
KCNJ5G151R are given for active compounds. See Supplemental Table 3 for detailed screen results.
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in CYP11B2 expression compared with cells transfected with 
KCNJ5WT. Roxithromycin inhibited expression of CYP11B2 in a 
dose-dependent fashion in cells expressing either KCNJ5G151R or 
KCNJ5L168R, whereas levels showed virtually no changes in cells 
expressing KCNJ5WT. Similar results were obtained for the synthe-
sized inhibitor PLUX38 (Figure 6C).
Discussion
These results demonstrate that specific macrolides selectively 
and potently inhibit channels harboring mutant forms of KCNJ5. 
The doses required to rescue overexpression-induced lethality 
are lower than those required to achieve near-complete channel 
inhibition, in line with the observation that moderate Na+ influx at 
physiological expression levels is associated with hyperplasia and 
tumor formation, rather than lethality, in vivo (7).
Prior exploration of candidate molecules (22) included inhibi-
tors of Na+/H+ exchangers, Na+/Ca2+ exchangers, calcium chan-
nels, and sodium channels. While several were shown to have 
some potency to inhibit KCNJ5L168R, the effect on KCNJ5G151R 
was reported for verapamil only (31% inhibition at high thera-
peutic levels, ref. 22; the compound did not pass the threshold 
for KCNJ5G151R inhibition in our primary screen), and effects on 
KCNJ5WT were not studied. Our 
study is the first we are aware of to 
perform an unbiased screen for com-
pounds that specifically inhibit both 
KCNJ5G151R and KCNJ5L168R and to 
have screened more than a handful of 
compounds. This demonstrates the 
value of using a robust high-through-
put screen. Our findings suggest that 
macrolides or related compounds 
could be used for the clinical diagno-
sis of APAs, eliminating the need for 
cost-intensive and invasive screen-
ing by adrenal venous sampling in a 
substantial number of cases. Because 
aldosterone synthase and aldoste-
rone both have short half-lives (38), 
short-term inhibition of expression 
of aldosterone synthase is sufficient 
to produce rapid reductions in plas-
ma and urinary aldosterone levels, as 
occurs with dexamethasone inhibi-
tion of aldosterone synthase expres-
sion in the Mendelian disease gluco-
corticoid-remediable aldosteronism 
(39). Thus, in patients in whom an 
APA is suspected from the finding of 
hypertension due to primary aldo-
steronism, short-term administra-
tion of an inhibitor of mutant KCNJ5 
would be expected to acutely reduce 
serum and urinary aldosterone levels 
in patients in whom somatic KCNJ5 
mutations are the cause of APAs. 
Tumors with KCNJ5 mutations are 
typically large (40), with characteristic morphology upon imag-
ing (41). Radiological evidence of such a unilateral adrenal tumor, 
in conjunction with the reduction in aldosterone production after 
pharmacological inhibition, would likely be sufficient to proceed 
to surgical intervention, obviating the need for invasive AVS. The 
large fraction of APAs caused by these mutations suggests that 
such a test would have substantial clinical impact. This approach 
to diagnosis could improve the identification of patients whose 
hypertension could be cured by surgical intervention.
Moreover, the long history of pharmacologic use of macrolides, 
with their established safety and oral bioavailability, suggests a use-
ful path forward for developing drugs similar to the tool compounds 
PLUX37 and PLUX38 that could be optimized for channel inhibi-
tion, lack of antibiotic and gastrointestinal effects, and pharmaco-
kinetics. The results thus far demonstrate structure activity rela-
tionships that can likely be built upon to achieve these goals, and a 
recent report on the fully synthetic assembly of 300 new macrolide 
candidates suggests further candidates for screening (42).
Even though spironolactone, a mineralocorticoid receptor 
antagonist, is available for the medical treatment of patients with 
APAs who elect not to undergo surgery, its use is associated with 
marked side effects, including gynecomastia, which often lim-
Figure 5. Roxithromycin inhibits KCNJ3/KCNJ5MUT-induced Na+ current and KCNJ5MUT-induced aldosterone 
production. (A) Cation currents were measured with the perforated whole cell recording (see Methods). 
Current-voltage plots of KCNJ3/KCNJ5G151R, KCNJ3/KCNJ5L168R, and KCNJ3/KCNJ5WT heterotetramers before and 
10 minutes after addition of 20 μM roxithromycin and 1 mM BaCl2 are shown. Shown are 3 (G151R, WT) or 4 
(L168R) biological replicates. (B) HAC15 cells stably transfected with KCNJ5WT, KCNJ5G151R, KCNJ5L168R, or empty 
vector were treated with the indicated concentrations of roxithromycin or with vehicle control for 6 hours. 
Aldosterone in the supernatant was quantified by ELISA and normalized to cell count (see Methods). Four 
independent experiments were performed for each condition (each measured in duplicate of 2 dilutions). (C) 
H295R cells transiently transfected with KCNJ5WT, KCNJ5G151R, KCNJ5L168R, or empty vector were treated with 
roxithromycin or vehicle control for 18 hours. CYP11B2 expression (with GAPDH as control) was determined 
by qPCR; 6 independent experiments were performed. Values were normalized to the respective values of 
empty vector. Error bars represent SEM. NS denotes P > 0.05. *P ≤ 0.05; **P ≤ 0.01; #P ≤ 0.001, Mann-Whit-
ney U test versus 0 μM roxithromycin.
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KCNJ5 channels are not expressed in rodent zona glomerulosa 
(44), and a mouse model of KCNJ5MUT largely does not replicate the 
human phenotype (45), hindering the testing of macrolide com-
pounds in animal models. The effect of macrolides on aldosterone 
production of primary cultures from APAs carrying KCNJ5MUT could 
be tested ex vivo (46), with limited informative value beyond our 
studies in H295R cells. The most promising path forward, however, 
involves clinical trials in humans. The potential of macrolides as 
diagnostic tools could be tested immediately with roxithromycin, 
which is marketed as an antibiotic in the European Union and whose 
safety has been established. After a single dose of 300 mg to healthy 
adults, maximum serum concentrations are 16.4 mg/l (~20 μM; 
half-life ~11 hours) (47), concentrations that strongly inhibit KCNJ3/
KCNJ5MUT heterotetramers and KCNJ5MUT homotetramers in vitro 
and reduce KCNJ5MUT-induced CYP11B2 expression by about 70% 
and KCNJ5MUT-induced aldosterone production by more than 50%. 
A decrease in blood pressure and/or aldosterone levels upon short-
term roxithromycin treatment that specifically occurs in KCNJ5MUT 
carriers (for clinical trials, mutation testing can be performed after 
routine surgery to correlate response to mutation) would therefore 
not only demonstrate diagnostic potential, but also provide addi-
tional support for the initiation of safety and efficacy studies of non-
antibiotic macrolide compounds in primary aldosteronism.
Methods
Generation of stable inducible HEK293 cell lines. WT or mutant human 
KCNJ5 cDNAs (7) were subcloned into the pcDNA5/FRT/TO vec-
its compliance. Eplerenone, a more selective mineralocorticoid 
receptor antagonist, is more expensive and not approved for the 
therapy of hypertension in Europe (4). In addition to a role in the 
diagnosis of APAs, it is also possible that long-term treatment with 
inhibitors of KCNJ5MUT could be efficacious in the treatment of 
hypertension in patients with APAs due to these mutations, poten-
tially eliminating the need for surgery. This may be particularly rel-
evant for patients who are poor surgical candidates. By inhibiting 
the proliferative signal as well as aldosterone production, it is also 
possible that the tumor might shrink with treatment, potentially 
eventually allowing withdrawal of therapy. In addition, inhibitors 
of KCNJ5MUT could be beneficial in individuals with rare germline 
KCNJ5 mutations who do not respond to therapy with mineralo-
corticoid antagonists and would otherwise require bilateral adre-
nalectomy (18). For long-term use, antibiotic and gastrointestinal 
effects would need to be eliminated from such a drug. Our studies 
indicate that channel inhibition can be separated from these other 
effects, affording promise that such inhibitors can be developed.
Finally, there is precedent for the pharmacologic treatment of 
hormone-producing tumors. Dopamine agonists have dramatical-
ly affected the treatment of prolactinomas, hormone-producing 
tumors of the pituitary gland. Dopamine agonists typically restore 
normal prolactin levels and reduce tumor mass, with recent 
data demonstrating that therapy can be withdrawn in a subset of 
patients after normalization of hormone levels and tumor disap-
pearance (43). These observations provide optimism that an anal-
ogous approach could have similar efficacy for APAs.
Figure 6. Inhibition of KCNJ5MUT by PLUX37 
and PLUX38. Cation currents of hetero-
tetramers of KCNJ3 and mutant or WT 
KCNJ5 were measured with the perforated 
patch-clamp technique without (blue) or 
with (red) 10 μM inhibitor (A) PLUX37 and 
(B) PLUX38. Extracellular solution: 140 
mM NaCl/5 mM KCl; intracellular solution: 
140 mM KCl. For both compounds, n = 5 
biological replicates for KCNJ3/KCNJ5G151R 
and KCNJ3/KCNJ5L168R; n = 4 for KCNJ3/
KCNJ5WT (mean and SEM). (C) H295R cells 
transiently transfected with KCNJ5WT, 
KCNJ5G151R, KCNJ5L168R, or empty vector were 
treated with PLUX38 or vehicle control for 
18 hours. CYP11B2 expression (with GAPDH 
as control) was determined by qPCR; 5 
independent experiments were performed. 
Values were normalized to the respective 
values of empty vector. Error bars repre-
sent SEM. NS denotes P > 0.05.  
**P ≤ 0.01, Mann-Whitney U test versus  
0 μM roxithromycin.
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Ligand Library, Protease Inhibitor Library (all 9 Enzo), and ChemDiv 
Library. Suppliers for compounds are indicated in Supplemental Tables 
1 and 2. Additional compounds and suppliers (Table 1) were as follows: 
roxithromycin (Sigma-Aldrich, R4393), idremcinal (Enzo, ALX-380-
264), pseudo erythromycin enol ether (Toronto Research, P839500), 
clarithromycin (Sigma-Aldrich, A3487), erythromycin B (Santa Cruz 
Biotechnology Inc., SC-362735), azithromycin (Sigma-Aldrich, 75199), 
anhydroerythromycin A (Toronto Research, A638950), erythromycin 
C (Santa Cruz Biotechnology Inc., SC-362736), erythromycin (Sigma-
Aldrich, E6376), dirithromycin (Sigma-Aldrich, D4065), and flurithro-
mycin (Waterstone Tech, 40589).
Cell viability assay. 20 μl of G151R and L168R cells was plated into 
sterile white with clear bottom tissue culture–treated 384-well plates 
(Corning) at a density of 2,000 cells/well (G151R) or 4,000 cells/
well (L168R) using a Multidrop Combi Reagent Dispenser (Thermo 
Scientific). Assay plates were centrifuged and incubated overnight at 
37°C, 5% CO2. 20 nl was transferred from the compound source plate 
to the cell assay plate using an Aquarius (Tecan) with a 384-well pin 
tool (V&P Scientific). The final concentration of compound for screen-
ing was 10 μM, and the final DMSO concentration was 0.1%. 1 μl of 
tetracycline (final concentration 1 μg/ml) was added to compound-
containing and negative control wells by Multidrop Combi to induce 
expression. 1 μl of media was added to positive control wells. Assay 
plates were centrifuged and incubated for 72 hours at 37°C, 5% CO2. 
CellTiter-Glo (Promega) was used to measure cell viability in the 
assay wells according to the manufacturer’s instructions. 10 μl/well of 
CellTiter-Glo reagent was added to the assay plates using a MultiDrop 
Combi. The plates were shaken on a Thermomixer R (Eppendorf) at 
1,100 rpm for 1 minute and incubated in the dark for 10 minutes at 
room temperature. Luminescence was read on an Envision plate read-
er (PerkinElmer) with 0.3 second sampling time per well. Raw data 
(luminescence counts per second) were normalized to percentage of 
effect by the following formula: 100 – (((sample – negative control 
mean)/(positive control mean – negative control mean)) × 100).
Membrane potential assay. 20 μl of WT cells were plated into sterile 
black with clear bottom tissue culture-treated 384-well plates (Corn-
ing) at a density of 10,000 cells/well using a Multidrop Combi. Assay 
plates were centrifuged at 46 g for 10 seconds and incubated overnight 
at 37°C in a humidified 5% CO2 incubator. After the overnight incu-
bation, 1 μl of tetracycline (final concentration, 1 μg/ml) was added 
to all wells by Multidrop Combi to induce KCNJ5. Assay plates were 
centrifuged at 46 g for 10 seconds and incubated overnight at 37°C in 
a humidified 5% CO2 incubator. The next day, 10 μl of medium was 
removed from each well using a PlateMate Plus (Thermo Scientific). 
10 μl of Blue Formula FLIPR Membrane Potential Dye (Molecu-
lar Devices) was added to cells using a multichannel pipettor. Assay 
plates were incubated for 30 minutes at 37°C. After incubation, 20 nl 
was transferred twice from the compound source plate to the cell assay 
plate using an Aquarius with a 384-well pin tool for a total transfer vol-
ume of 40 nl and a final DMSO concentration of 0.2%. 1 μl of 20 mM 
BaCl2 (1 mM final concentration) was added to positive control wells 
using a multichannel pipettor, and results were defined as 100% inhi-
bition. The assay plate was incubated 20 minutes at room temperature 
in the dark. Fluorescence was read in a FlexStation II 384 plate reader 
(Molecular Devices) at 530/565 nm ex/em, bottom read.
Synthesis of macrolide derivatives. The synthesis of PLUX30B, -31A, 
-32, -33, -35A, -37 and -38, -40 (50), and PLUX36 (28) was performed 
tor using BamHI and HindIII. Single copies of WT or mutant human 
KCNJ5 cDNAs expressed under the control of a tetracycline-inducible 
promoter were introduced into HEK293 cells using the Flp-In T-REx 
System (Invitrogen) according to the manufacturer’s instructions. 
Cells were grown in selective media containing 10% Tet System 
Approved FBS (Clontech) until induction.
Generation of HAC15 cell lines stably expressing KCNJ5. HAC15 cells 
(a gift of William Rainey, University of Michigan, Ann Arbor, Michigan, 
USA) authenticated by short tandem repeat (STR) analysis (ATCC Cell 
Line Authentication Service) and tested for mycoplasma (Lonza Myco-
Alert Mycoplasma Detection Kit) were cultured at 37°C and 5% CO2 in 
DMEM:F12 (1:1, Gibco, Thermo Fisher Scientific) supplemented with 
5% Cosmic Calf Serum (CCS) (Hyclone Laboratories), 1% penicillin/
streptomycin, 1% insulin-transferrin-selenium, 1% nonessential amino 
acids, and 0.1% lipid mixture (all Gibco, Thermo Fisher Scientific). 
HEK293T cells were cultured in DMEM (Biochrom) with 10% FBS 
(Biochrom) and 1% penicillin/streptomycin (Gibco, Thermo Fisher 
Scientific) in 5% CO2 at 37°C.
pLX303 KCNJ5G151R, pCMV-VSV-G, and psPAX2 were gifts of C. 
Gomez-Sanchez (University of Mississippi Medical Center, Jackson, 
Mississippi, USA) (48). pLX303 KCNJ5WT was generated from plx303 
KCNJ5G151R using a PCR-based strategy (QuikChange, Stratagene) 
according to the manufacturer’s instructions, and pLX303 KCNJ5L168R 
was similarly generated from plx303 KCNJ5WT. pLX303 empty vector 
was generated by digest of pLX303 KCNJ5G151R with BsrGI (NEB) and 
self-ligation. Plasmids for transduction were prepared using the QIA-
GEN Maxi Plus Kit. For lentiviral production, HEK293T cells were 
seeded in T75 flasks and transfected with pLX303 constructs, pCMV-
VSV-G, and psPAX2 in a molar ratio of 12:8:14 (total DNA amount 33.5 
μg, filled up to 610 μl with PBS) plus 96 μg polyethylenimine ([PEI]87) 
(a gift of C. Gomez-Sanchez) in 610 μl PBS. After 20 minutes incuba-
tion, 12.4 ml medium containing roxithromycin to a final concentra-
tion of 20 μM was added. After overnight incubation, the medium was 
changed. After 48 hours, the supernatant containing the lentivirus 
was harvested, centrifuged at 1,690 g and 4°C for 30 minutes, filtered 
through a 0.45-μM particle filter, and frozen at –80°C. For spinocula-
tion (49), HAC15 cells were seeded in 24-well plates at 150,000 cells 
per well. The next day, 0.9 ml supernatant containing lentivirus and 
0.8 μg/ml polybrene (Hexadimetrinebromide, Sigma-Aldrich) were 
added to each well. The plates were centrifuged for 2 hours at 1,200 g 
and 15°C and incubated at 37°C, 5% CO2 for 4 hours. The medium was 
changed to HAC15 medium containing 20 μM roxithromycin. The fol-
lowing day, the spinoculation was repeated. Selection was performed 
with 5 μg/ml blasticidin in the presence of 20 μM roxithromycin. Cor-
rect genotypes and transgene expression were verified by RNA isola-
tion and Sanger sequencing of KCNJ5 cDNA.
Compound libraries. All compound libraries were from the Yale 
Center for Molecular Discovery Research Collection. Compound 
libraries are formatted as 10 mM stocks in DMSO. For dilution curves, 
10 mM stocks of compounds in DMSO were prepared and diluted 2-fold 
serially in DMSO. In the primary screen, the following libraries were 
screened: Gen-Plus, Pure Natural Products, Pharmakon 1600 (all 3 
Microsource), NIH Clinical Collection, Oncology Set 2, Diversity Set 2, 
Mechanistic Diversity Set, Natural Products Set (all 4 NCI), Epigenetics 
Library, Kinase Inhibitor Library, Phosphatase Inhibitor Set, Ion Chan-
nel Ligand Library, Bioactive Lipid Library, Metabotropic Glutama-
tergic Ligand Library, 640 FDA-approved drugs, Nuclear Receptor 
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reach the designated concentrations. To determine the Ba2+-sensitive 
K+ currents, we used 1 mM BaCl2 at the end of experiments. For the 
examination of the effect of roxithromycin on cation currents in cells 
transfected with KCNJ5 mutants (G151R or L168R), 1 mM BaCl2 was 
present in the bath solution throughout the experiments.
Within 24 hours after transfection, cells were treated with trypsin-
containing medium (TrypLE Express) (Gibco, Thermo Fisher Scien-
tific) for 10 minutes to detach the cells. We carried out the perforated 
whole-cell patch-clamp experiments at room temperature. The cells 
were incubated with a KCl bath solution containing 140 mM KCl, 1.8 
mM MgCl2, 1.8 mM CaCl2, and 10 mM HEPES (pH 7.4) or with a Na 
Ringer bath solution (140 mM NaCl, 5 mM KCl, 1.8 mM MgCl2, 1.8 
mM CaCl2, and 10 mM HEPES). Fluorescence signal (an indication of 
positive transfection) was detected with an intensified video imaging 
system including a SIT 68 camera (Long Island Industries). Borosili-
cate glass (1.7-mm OD) was used to make the patch-clamp pipettes 
that were pulled with a Narishege electrode puller. The pipette had 
a resistance of 2–4 MΩ when filled with 140 mM KCl. The tip of the 
pipette was filled with pipette solution containing 140 mM KCl, 2 mM 
MgCl2, 1 mM EGTA, and 5 mM HEPES (pH 7.4). The pipette was then 
back-filled with amphotericin B (20 μg/0.1 ml) containing pipette 
solution. After forming a high-resistance seal (>2 GΩ), the membrane 
capacitance was monitored until the whole-cell patch configuration 
was formed. The cell membrane capacitance was measured and com-
pensated. The K/cation currents were measured from –80 mV to 20 
mV with 20 mV steps by an Axon 200A patch-clamp amplifier. The 
currents were low-pass filtered at 1 KHz and digitized by an Axon 
interface (Digidata 1200) and were analyzed using the pClamp Soft-
ware System 9 (Axon). Data are presented as mean ± SEM.
Real-time PCR. H295R cells (a gift of Matthias Haase), authenti-
cated by STR analysis (ATCC Cell Line Authentication Service) and 
tested for mycoplasma (Lonza MycoAlert Mycoplasma Detection Kit), 
were cultured in DMEM/F12, HEPES (Gibco, Thermo Fisher Scientif-
ic) supplemented with 2.5% Ultroser G (Pall Biosepra), 1% ITS+ Premix 
(Corning), and 1% penicillin/streptomycin (Gibco, Thermo Fisher Sci-
entific) at 37°C and 5% CO2. Plasmids were purified using the Endo-
Free Maxi Kit (QIAGEN). Roxithromycin stock solutions were 100 mM 
in DMSO (both Sigma-Aldrich). PLUX38 stock concentration was 50 
mM in DMSO. 3 × 106 cells were transfected with 3 μg pIRES2 EGFP 
containing no insert and WT or mutant KCNJ5 using an Amaxa Nucleo-
fector device (program P-20) and the Nucleofector Kit R (Lonza). Cells 
were allowed to recover briefly in RPMI 1640 medium (Gibco, Thermo 
Fisher Scientific). Transfected cells were resuspended in medium con-
taining 20 μM roxithromycin and plated on a 12-well plate. Transfec-
tion was confirmed via fluorescence microscopy. After 25 hours, cells 
were washed with PBS, and medium containing 0.1% Ultroser G and 
DMSO (vehicle) and 5, 20, or 50 μM compound was added. After an 
additional 18 hours, RNA was harvested using the RNeasy Mini Kit 
(QIAGEN) following the manufacturer’s instructions. 300 ng RNA 
was transcribed using the Quantitect Reverse Transcription Kit (QIA-
GEN). Ct levels of CYP11B2 and GAPDH were determined in triplicate 
in a 7300 Real-Time PCR System (Applied Biosystems) using TaqMan 
Gene Expression Master Mix and assays Hs01597732_m1 (CYP11B2) or 
HS02758991_g1 (GAPDH) (all Applied Biosystems). ΔCt values were 
calculated by subtracting GAPDH Ct from CYP11B2 Ct, and ΔΔCt val-
ues were calculated by subtracting the average ΔCt of vehicle-treated 
empty vector–transfected cells from each ΔCt value. Fold changes in 
as previously described. The acylation reaction needed to synthesize 
PLUX34, -39, and -42 has also been described in the literature (51). 
The synthesis of PLUX33 or N-demethyl-9-deoxo-9-hydroxy-N-butyl-
(9S)-erythromycin was made in a manner identical to that of PLUX32, 
only 1-iodobutane was used as the alkylating agent. Crude product 
was purified by silica gel chromatography, eluting with 6% (8:1, etha-
nol/ammonium hydroxide) in ethyl acetate to give 142 mg, 52% prod-
uct as a colorless solid. 1H NMR peaks (400 MHz, DMSO-d6) were as 
follows: 1H NMR (400 MHz, DMSO-d6) δ 5.56 (d, J = 5.7 Hz, 1H), 4.92 
(d, J = 9.8 Hz, 1H), 4.79 (d, J = 4.7 Hz, 1H), 4.53 (s, 1H), 4.39 (d, J = 2.1 
Hz, 1H), 4.28 (d, J = 7.4 Hz, 1H), 3.86 (m, 5H), 3.70 (s, 1H), 3.59 (d, J = 
5.1 Hz, 1H), 3.55(2, 1H), 3.20 (s, 3H), 3.04 (d, J = 8.5 Hz, 2H), 2.88 (dd, J 
= 9.4, 7.4 Hz, 1H), 2.67(m,1H), 2.54 (m, 1H), 2.48(m, 1H), 2.32 (m, 1H), 
2.27 (d, J = 15.2 Hz, 1H), 2.15 (s, 3H), 1.89 (s, 1H), 1.73 (m, 3H), 1.56(d, 
J = 10.9 Hz, 1H) 1.46 (m, 2H), 1.40-1.19 (m, 5H), 1.15- 0.92 (m, 29H), 
0.85 (t, J = 7.2 Hz, 3H), 0.74 (t, J = 7.4 Hz, 3H). m/z: 778 [M+H]+ (found 
[M+H]+, 778.5310, requires C40H75NO13 [M+H]
+ 778.5317). PLUX36 or 
N-demethyl-8,9-anhydroerythromycin A 6,9-hemiacetal and PLUX37 
or N-demethyl- N-isobutyl-8,9-anhydroerythromycin A 6,9-hemi-
acetal were synthesized as previously described (28). PLUX40 or 
N-demethyl-N-(2-methylpropyl)-erythromycin was produced by 
alkylating known N-demethylerythromycin in a manner identical to 
that done with PLUX32, using 1-iodo-2-methylpropane as the alkylat-
ing agent. Crude product was purified by silica gel chromatography 
eluting with 4% (8:1, ethanol/ammonium hydroxide) in dichloro-
methane to give product 85 mg, 52% yield. 1H NMR peaks (400 MHz, 
DMSO-d6) were as follows: 
1H NMR (400 MHz, DMSO-d6) δ 5.13 – 
5.04 (m, 1H), 4.72 (d, J = 4.8 Hz, 1H), 4.50 (s, 1H), 4.36 (d, J = 7.6 Hz, 
1H), 4.30 – 4.23 (m, 2H), 4.08 – 3.94 (m, 2H), 3.90 – 3.82 (m, 2H), 3.75 
(dd, J = 5.9, 2.0 Hz, 1H), 3.60 (s, 1H), 3.46 (d, J = 7.2 Hz, 1H), 3.19 (s, 
3H), 3.03 (td, J = 8.0, 7.5, 3.8 Hz, 1H), 2.93 – 2.71 (m, 4H), 2.65 (m, 1H), 
2.46 – 2.38 (m, 1H), 2.33 – 2.08 (m, 6H), 1.92 – 1.60 (m, 5H), 1.60 – 1.45 
(m, 3H), 1.43-1.32 (m, 2H), 1.26 (s, 4H), 1.15 (d, J = 6.1 Hz, 3H), 1.11 (s, 
3H), 1.09 (d, J = 7.3 Hz, 3H), 1.07-1.01 (m, 6H), 1.02-0.96 (m, 6H), 0.82 
(dd, J = 6.5, 2.6 Hz, 6H), 0.74 (t, J = 7.4 Hz, 3H) m/z: 776 [M+H]+ (found 
[M+H]+, 776.5184, requires C40H73NO13 [M+H]
+ 776.5160).
Kirby-Bauer disk diffusion assay. Staphylococcus aureus (ATCC 
25923) was streaked on Kirby-Bauer plates. 18 nmol compound was 
added to a sterile filter paper disk and placed on the plate. After incu-
bation at 37°C, the diameter of the inhibitory zone was recorded.
Electrophysiology. HEK293T cells (ATCC) were used for transient 
expression of GFP-tagged KCNJ5 or KCNJ3. The cells were grown in 
DMEM (Invitrogen) supplemented with 10% FBS (Invitrogen) in 5% 
CO2 and 95% air at 37°C. Cells were grown to 50%–70% confluence 
for transfection, and the corresponding cDNAs (7) were simultaneous-
ly applied to the cells using TurboFect transfection reagent according 
to the manufacturer’s protocol (Fermentas). Briefly, a cDNA cocktail 
(0.5 μg GFP-tagged KCNJ5 and 0.5 μg KCNJ3) was diluted with 200 μl 
serum-free DMEM and further mixed with 4 μl TurboFect transfection 
reagent for the transfection of cells cultured in 35-mm Petri dishes. For 
studying the K+/cation channel activity of homotetramer KCNJ5, we 
used 1 μg cDNA for transfection. Cells transfected with vector alone 
were used as a control, and their background currents were subtracted 
from the experimental groups. After 15 minutes incubation at room 
temperature, the mixture of the transfection agents was applied to 
the cells followed by an additional 24 hours of incubation before use. 
Roxithromycin (Sigma-Aldrich) was dissolved in the bath solution to 
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tributed to cell maintenance. LA, UIS, and JSM designed and 
performed high-throughput screening assays. MP synthesized 
compounds. CZ and WW performed and analyzed electrophysi-
ology. ENR performed qPCR analysis and ELISAs. UIS and BIK 
performed Kirby-Bauer disk-diffusion assays. UIS prepared fig-
ures and tables. UIS and RPL wrote and edited the main text and 
supplemental data. UIS, DH, JSM, WW, and RPL oversaw parts of 
the project or had advisory roles.
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expression levels are shown as 2–ΔΔCt, normalized to the value of vector-
transfected cells at the respective inhibitor concentration.
Aldosterone ELISA. 250,000 stably transfected HAC15 cells/well 
were seeded on a white clear-bottom 96-well plate (Corning). After 24 
hours, cells were washed with PBS, and medium was changed to 0.1% 
CCS, 1% penicillin/streptomycin, 1% nonessential amino acids, 1% ITS, 
and 0.1% lipid concentrate (all Gibco, Thermo Fisher Scientific), with 20 
μM roxithromycin, but no blasticidin. After an additional 24 hours, cells 
were again washed with PBS, and medium containing 0, 5, 20, or 50 μM 
roxithromycin was added. After 6 hours, the plate was centrifuged, the 
supernatant removed, and 100 μl of medium containing the same rox-
ithromycin concentration as before was added. After 45 minutes incu-
bation at room temperature, a CellTiter-Glo assay (Promega) was per-
formed according to the manufacturer’s instructions. Luminescence was 
analyzed on an Enspire 2300 Multilabel Reader (PerkinElmer) with a 
measurement time of 0.25 seconds. Cell supernatants were centrifuged 
again, transferred to a fresh tube, and frozen at –20°C. They were ana-
lyzed in duplicate at 2 dilutions using the Cayman Aldosterone EIA Kit 
(catalog 501090) following the manufacturer’s instructions. For values 
outside the assay range, both replicates of the respective dilution were 
removed from the analysis. Cell counts were interpolated in GraphPad 
Prism using a nonlinear fit of the standard curve of 1,000,000, 750,000, 
500,000, 250,000, 125,000, 62,500, 31,250, and 15,625 cells seeded in 
triplicate. Aldosterone per well was normalized to cell count.
Statistics. Data were analyzed using the programs Excel (Micro-
soft) and Prism (GraphPad). Error bars are shown as SD unless other-
wise indicated in the legend. Dose-response curves were fitted with 
the following 4-parameter logistic equation:
    (Equation 1)
where y = dependent variable, a = minimum inhibition, d = maximum 
inhibition, x = independent variable, c = inflection point, and b = Hill’s 
slope. For Student’s t test, data passed normality tests in Prism. P ≤ 
0.05 was considered statistically significant.
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